Insights into Newer Antimicrobial Agents against Gram-negative Bacteria | Zendy

Neelam Yaneja | Zendy; Harsimran Kaur | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Insights into Newer Antimicrobial Agents against Gram-negative Bacteria

Author(s) -

Neelam Yaneja,

Harsimran Kaur

Publication year - 2016

Publication title -

microbiology insights

Language(s) - English

Resource type - Journals

ISSN - 1178-6361

DOI - 10.4137/mbi.s29459

Subject(s) - colistin , antibiotics , acinetobacter , antimicrobial , rifampicin , biology , gram negative bacteria , acinetobacter baumannii , antibiotic resistance , intensive care medicine , microbiology and biotechnology , medicine , bacteria , pseudomonas aeruginosa , escherichia coli , biochemistry , genetics , gene

Currently, drug resistance, especially against cephalosporins and carbapenems, among gram-negative bacteria is an important challenge, which is further enhanced by the limited availability of drugs against these bugs. There are certain antibiotics (colistin, fosfomycin, temocillin, and rifampicin) that have been revived from the past to tackle the menace of superbugs, including members of Enterobacteriaceae, Acinetobacter species, and Pseudomonas species. Very few newer antibiotics have been added to the pool of existing drugs. There are still many antibiotics that are passing through various phases of clinical trials. The initiative of Infectious Disease Society of America to develop 10 novel antibiotics against gram-negative bacilli by 2020 is a step to fill the gap of limited availability of drugs. This review aims to provide insights into the current and newer drugs in pipeline for the treatment of gram-negative bacteria and also discusses the major challenging issues for their management.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research